COSELA may increase cisplatin exposure and kidney accumulation, causing dose-related nephrotoxicity. Close monitoring required.
Source: NLP:trilaciclib
Trilaciclib Interactions
Brand names: Cosela
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS COSELA is contraindicated in patients with a history of serious hypersensitivity reactions to trilaciclib. Reactions have included anaphylaxis [see Warnings and Precautions ( 5.2 )] . Patients with a history of serious hypersensitivity reactions to COSELA. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary Based on the mechanism of action, COSELA can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12 )] . There are no available human or animal data on COSELA use to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. However, the background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies in the United States general population.
3 interactions on record
COSELA inhibits OCT2 and may increase dalfampridine blood levels, elevating risk of seizures.
Source: NLP:trilaciclib
COSELA inhibits OCT2 and may increase dofetilide concentration, causing serious ventricular arrhythmias and QT interval prolongation including torsade de pointes.
Source: NLP:trilaciclib